Opinion|Videos|January 2, 2025
Emerging Data for Odronextamab in DLBCL
Panelists discuss how emerging data on odronextamab in diffuse large B-cell lymphoma suggest its potential to play a significant role in therapy, with promising results that may position it alongside or as a superior option compared with currently approved bispecifics.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What do the emerging data on odronextamab in diffuse large B-cell lymphoma suggest about its future role in therapy, and how does it compare to currently approved bispecifics?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Tozorakimab Cuts COPD Exacerbations Up to 34% in Phase 3 Trials
2
The True Cost of Running a Community CAR T-Cell Program
3
Bringing CAR T-Cell Therapy Into Community Cancer Centers
4
Trump Admin Awards $106M to Expand Rural Health Care in NY, RI, MI
5